DACH1 and esophageal cancer: In conclusion, DACH1 methylation in esophageal cancer may be involved in disease onset and progression, and patients with DACH1 methylation have low sensitivity to radiotherapy and poor prognosis, which is expected to be a new indicator for diagnosis, disease and prognosis assessment, and efficacy monitoring of esophageal cancer.